Simple item page
 

Effects of dietary seaweed on obesity-related metabolic status: a systematic review and meta-analysis of randomized controlled trials

cris.virtual.author-orcid0000-0003-1996-5198
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid0000-0002-2268-9326
cris.virtualsource.author-orcid1ccb8edd-cf11-49a4-bd1c-af5fd753fdc7
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid190a1224-971b-4b6e-a791-aa08ba93ca89
dc.abstract.enContext Seaweed is a promising source of anti-obesity agents, including polysaccharides, proteins, polyphenols, carotenoids, and n-3 long-chain polyunsaturated fatty acids. The anti-obesity effects of such compounds may be due to several mechanisms, including inhibition of lipid absorption and metabolism, effect on satiety, and inhibition of adipocyte differentiation. Objective The aim of this study was to assess the evidence from human randomized controlled trials for the effects of seaweed on body-weight status as well as lipid and nonlipid parameters in adults with overweight and obesity. Data Sources Four databases—Medline, Scopus, Web of Science, and Cochrane Library—were searched from December 2022 to June 2023 using the following key words: Seaweed OR fucoxanthin OR alginates OR fucoidans OR phlorotannin’s OR macroalgae OR marine algae AND obesity OR overweight OR BMI OR body mass index. Data Extraction Eleven interventional studies (10 parallel and 1 crossover) were extracted. Data Analysis Meta-analysis showed a significant effect, favoring the intervention group for BMI (body mass index) (standardized mean difference [SMD]: -0.40; 95% CI: -0.65 to -0.16 kg/m2; P = 0.0013) and percentage of fat mass (SMD: -1.48; 95% CI: -2.66% to -0.30%, P = 0.0138). The results were seen when refined or extracted brown seaweed (BMI) or only refined brown seaweed (% fat mass) were administered to participants for at least 8 weeks. Moreover, a significant overall effect of seaweed supplementation on total cholesterol (SMD: -7.72; 95% CI: -12.49 to -2.95 mg/dL; P = 0.0015) and low-density-lipoprotein cholesterol (SMD: -7.33; 95% CI: -11.64 to -3.02 mg/dL; P < 0.001) was noted. Any significant effects of seaweed on glucose metabolism were not shown. Conclusion Edible seaweed supplementation shows potential for managing obesity and disorders of the blood lipid profile when administered to participants for at least 8 weeks.
dc.affiliationWydział Nauk o Żywności i Żywieniu
dc.affiliation.instituteKatedra Żywienia Człowieka i Dietetyki
dc.contributor.authorŁagowska, Karolina
dc.contributor.authorJurgoński, Adam
dc.contributor.authorMori, Mari
dc.contributor.authorYamori, Yukio
dc.contributor.authorMurakami, Shigeru
dc.contributor.authorIto, Takashi
dc.contributor.authorToda, Toshiya
dc.contributor.authorPieczyńska-Zając, Joanna Maria
dc.contributor.authorBajerska, Joanna
dc.date.accessioned2024-08-22T11:19:55Z
dc.date.available2024-08-22T11:19:55Z
dc.date.issued2024
dc.description.abstract<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Context</jats:title> <jats:p>Seaweed is a promising source of anti-obesity agents, including polysaccharides, proteins, polyphenols, carotenoids, and n-3 long-chain polyunsaturated fatty acids. The anti-obesity effects of such compounds may be due to several mechanisms, including inhibition of lipid absorption and metabolism, effect on satiety, and inhibition of adipocyte differentiation.</jats:p> </jats:sec> <jats:sec> <jats:title>Objective</jats:title> <jats:p>The aim of this study was to assess the evidence from human randomized controlled trials for the effects of seaweed on body-weight status as well as lipid and nonlipid parameters in adults with overweight and obesity.</jats:p> </jats:sec> <jats:sec> <jats:title>Data Sources</jats:title> <jats:p>Four databases—Medline, Scopus, Web of Science, and Cochrane Library—were searched from December 2022 to June 2023 using the following key words: Seaweed OR fucoxanthin OR alginates OR fucoidans OR phlorotannin’s OR macroalgae OR marine algae AND obesity OR overweight OR BMI OR body mass index.</jats:p> </jats:sec> <jats:sec> <jats:title>Data Extraction</jats:title> <jats:p>Eleven interventional studies (10 parallel and 1 crossover) were extracted.</jats:p> </jats:sec> <jats:sec> <jats:title>Data Analysis</jats:title> <jats:p>Meta-analysis showed a significant effect, favoring the intervention group for BMI (body mass index) (standardized mean difference [SMD]: -0.40; 95% CI: -0.65 to -0.16 kg/m2; P = 0.0013) and percentage of fat mass (SMD: -1.48; 95% CI: -2.66% to -0.30%, P = 0.0138). The results were seen when refined or extracted brown seaweed (BMI) or only refined brown seaweed (% fat mass) were administered to participants for at least 8 weeks. Moreover, a significant overall effect of seaweed supplementation on total cholesterol (SMD: -7.72; 95% CI: -12.49 to -2.95 mg/dL; P = 0.0015) and low-density-lipoprotein cholesterol (SMD: -7.33; 95% CI: -11.64 to -3.02 mg/dL; P &amp;lt; 0.001) was noted. Any significant effects of seaweed on glucose metabolism were not shown.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>Edible seaweed supplementation shows potential for managing obesity and disorders of the blood lipid profile when administered to participants for at least 8 weeks.</jats:p> </jats:sec> <jats:sec> <jats:title>Systematic Review Registration</jats:title> <jats:p>PROSPERO registration no. CRD42022378484 (www.crd.york.ac.uk/PROSPERO).</jats:p> </jats:sec>
dc.description.bibliographybibliogr.
dc.description.financepublication_nocost
dc.description.financecost0,00
dc.identifier.doi10.1093/nutrit/nuae042
dc.identifier.eissn1753-4887
dc.identifier.issn0029-6643
dc.identifier.urihttps://sciencerep.up.poznan.pl/handle/item/1678
dc.languageen
dc.relation.ispartofNutrition Reviews
dc.rightsClosedAccess
dc.sciencecloudnosend
dc.subject.enalginate
dc.subject.enbrown seaweeds
dc.subject.enfucoidan
dc.subject.enfucoxanthin
dc.subject.enoverweight
dc.subject.enobesity
dc.subtypeArticleEarlyAccess
dc.titleEffects of dietary seaweed on obesity-related metabolic status: a systematic review and meta-analysis of randomized controlled trials
dc.typeJournalArticle
dspace.entity.typePublication
project.funder.nameb.d.